Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare ...

Fridays weight loss is a telehealth provider that offers access to popular GLP-1 medications, including compounded versions ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

The president of Omada Health talks about why decision makers need to be thinking about holistic weight-management care as ...

Doctors and patients have been hoping for a pill version that would be easier to take, in contrast to an injectable.

Looking for the most shorted stocks?

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...